ArticleBMC biotechnology2026
Development of a nanoemulsion incorporating 3-acetyl-11-keto-β-boswellic acid (AKBA): solubility and oral bioavailability through in vitro and in vivo studies.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
background3-Acetyl-11-keto-β-boswellic acid (AKBA) has attracted considerable interest due to its therapeutic potential against inflammatory and cancer-related disorders. However, its poor oral bioavailability remains a critical limitation for clinical application. This study aimed to enhance the bioavailability of AKBA by developing a nanoemulsion (NE)-based delivery system.
resultsSeveral NE formulations were optimized and characterized based on drug loading, stability, and droplet size. The optimized NE-AKBA showed a droplet size of 12-15 nm, a low polydispersity index, and a zeta potential of - 14.5 mV. Permeability studies revealed significantly improved transport of NE-AKBA across Caco-2 monolayers within the first hour. Pharmacokinetic analysis revealed a notable increase in systemic exposure: C
conclusionThese findings demonstrate that nanoemulsion-based delivery significantly improves the oral bioavailability of AKBA and provides a promising platform for its future therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.